Tag Archive for: Phase 1

DelSiTech Announces Positive Topline Clinical Data From Phase 1 Trial With Its Sustained Release Eye Drop Platform

Turku, Finland – 29th June 2023: Drug delivery and development company DelSiTech today reported positive topline results from its Phase 1 clinical trial, evaluating the safety and tolerability of DST-2105, DelSiTech’s first of its kind, silica-based, long-acting demulcent eye drop product. Read more…  

Vicore initiates clinical proof-of-concept study of endothelial dysfunction

Stockholm, May 3, 2023 – Vicore Pharma Holding AB (STO: VICO) (“Vicore”), unlocking the potential of a new class of drugs – angiotensin II type 2 receptor agonists (ATRAGs), today announces the first patient dosed with C21 in a clinical study of endothelial dysfunction. Endothelial dysfunction is a key driver of organ damage associated with […]

MinervaX Commences First Phase 1 Clinical Study of Novel GBS Vaccine in Older Adults

Expands development of novel GBS vaccine in older adult population Targeting significant and growing unmet medical need of GBS infection Copenhagen, Denmark, 17 April 2023 – MinervaX ApS, a privately held Danish biotechnology company developing a novel vaccine against Group B Streptococcus (GBS), announces the first phase 1 clinical study in older adults of its […]

Verona Pharma Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Access to up to $400 million expected to provide cash runway through at least 2025 Top-line Phase 3 ENHANCE-1 data expected around the end of 2022 Conference call today at 9:00 a.m. EST / 2:00 p.m. GMT LONDON and RALEIGH, N.C., Nov. 09, 2022 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or […]

CellCentric secures investment from the American Cancer Society’s impact venture capital fund

Inobrodib is the first drug to target p300/CBP, a new way to treat specific cancers.  Following a successful Phase I campaign, new funding will be used to progress clinical development towards to pivotal registration trials. Cambridge, UK, 26 January 2022 – CellCentric, a clinical stage, private biotechnology company pioneering small molecule inhibition of p300/CBP to treat […]